Search

Your search keyword '"A. Scalisi"' showing total 47 results

Search Constraints

Start Over You searched for: Author "A. Scalisi" Remove constraint Author: "A. Scalisi" Publisher elsevier ltd Remove constraint Publisher: elsevier ltd
47 results on '"A. Scalisi"'

Search Results

3. Efficacy of 1 L polyethylene glycol plus ascorbate versus 4 L polyethylene glycol in split-dose for colonoscopy cleansing in out and inpatient: A multicentre, randomized trial (OVER 2019)

4. Neonates undergoing pyloric stenosis repair are at increased risk of difficult airway management: secondary analysis of the NEonate and Children audiT of Anaesthesia pRactice IN Europe

6. Morbidity and mortality after anaesthesia in early life: results of the European prospective multicentre observational study, neonate and children audit of anaesthesia practice in Europe (NECTARINE)

7. Difficult tracheal intubation in neonates and infants. NEonate and Children audiT of Anaesthesia pRactice IN Europe (NECTARINE): a prospective European multicentre observational study

10. Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe

12. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study”

16. Current practice of hepatitis C treatment in Southern Italy

17. Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

19. PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

20. Corrigendum to ‘Difficult tracheal intubation in neonates and infants. NEonate and Children audiT of Anaesthesia pRactice IN Europe (NECTARINE): a prospective European multicentre observational study’ (Br J Anaesth 2021; 126: 1173–81)

24. Second-generation DAAs for HCV: real-life efficacy in the RESIST-HCV cohort

26. OC.07.1 DIRECT ACTING ANTIVIRALS AFTER SUCCESSFUL TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA IMPROVE SURVIVAL AND REDUCE HEPATIC DECOMPENSATION IN HCV-CIRRHOTIC PATIENTS

27. PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT

28. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

32. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort

34. Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs)

35. Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs)

36. Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis

37. Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry

39. Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database

Catalog

Books, media, physical & digital resources